SLC28A1抗体;SLC28A1 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 293T cell lysate, Primary antibody: P13732(SLC28A1 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13732(SLC28A1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The SLC28A1 gene encodes concentrative nucleoside transporter 1 (CNT1), a protein belonging to the solute carrier family 28 (SLC28), which facilitates sodium-dependent uptake of nucleosides and nucleoside analog drugs across cell membranes. Primarily expressed in the kidneys, liver, intestines, and certain immune cells, SLC28A1 plays a critical role in mediating cellular absorption of pyrimidine nucleosides (e.g., uridine, thymidine) and clinically relevant therapeutics like anticancer agents (e.g., gemcitabine) or antiviral drugs (e.g., zalcitabine). Its function impacts nucleotide biosynthesis, drug pharmacokinetics, and cellular responses to nucleoside-based therapies.

SLC28A1-specific antibodies are immunological tools designed to detect and quantify CNT1 protein expression in research applications. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to study tissue-specific expression patterns, subcellular localization, and regulatory changes in disease contexts. Validated antibodies help explore SLC28A1's involvement in cancer drug resistance, genetic disorders of nucleoside metabolism, or interactions with pharmacological agents.

When selecting SLC28A1 antibodies, specificity and cross-reactivity with other SLC28 isoforms (e.g., CNT2/SLC28A2. CNT3/SLC28A3) must be confirmed via knockout controls or peptide-blocking assays. High-quality antibodies are essential for elucidating CNT1's physiological roles and its potential as a biomarker or therapeutic target. Researchers should verify antibody performance in their experimental systems using appropriate positive controls (e.g., tissues with known CNT1 expression) and cite peer-reviewed validation data.